Join the Tecentriq group to help and get support from people like you.
Tecentriq News
Atezolizumab + Chemo After Surgery Does Not Improve Survival for Triple-Negative Breast Cancer
THURSDAY, March 28, 2024 – Patients with triple-negative breast cancer do not benefit from the addition of atezolizumab to their postsurgery chemotherapy treatment, according to a study presented at...
Atezolizumab Plus Standard Care Improves Survival in Advanced Cervical Cancer
FRIDAY, Jan. 5, 2024 – For patients with metastatic, persistent, or recurrent cervical cancer, adding atezolizumab to a standard bevacizumab plus platinum regimen significantly improves...
Atezolizumab Can Induce Response in Alveolar Soft Part Sarcoma
THURSDAY, Sept. 7, 2023 – The immunotherapy agent atezolizumab induces sustained responses in about one-third of patients with advanced alveolar soft part sarcoma (ASPS), according to a study...
T-Cell Tolerant Fraction Can Predict Immunotherapy Toxicity
MONDAY, Aug. 21, 2023 – The T-cell tolerant fraction predicts clinically significant immune-related adverse events (irAEs) among patients with cancer treated with immune checkpoint inhibitors...
Atezolizumab Monotherapy Beneficial for NSCLC Ineligible for Platinum-Based Chemo
TUESDAY, Aug. 15, 2023 – For patients with non-small cell lung cancer (NSCLC) ineligible for platinum-based chemotherapy, first-line atezolizumab monotherapy is associated with improved overall...
2 Years of Immunotherapy for Advanced Lung Cancer Might Be Enough: Study
FRIDAY, June 9, 2023 – For patients battling late-stage lung cancer, prospects for survival have improved significantly since the advent of medications known as immune checkpoint inhibitors. But...
ASCO: Adding Atezolizumab to Cabozantinib No Benefit in Advanced Renal Cancer
FRIDAY, June 9, 2023 – For patients with locally advanced or metastatic renal cell carcinoma with disease progression on or after immune checkpoint inhibitor treatment, the addition of atezolizumab...
Genentech Provides Update on Tecentriq U.S. Indication for Previously Untreated Metastatic Bladder Cancer
South San Francisco, CA – November 28th, 2022 -- Genentech, a member of the Roche Group, today announced that the company is voluntarily withdrawing the U.S. indication of Tecentriq® (atezolizumab) f...
FDA Approves Genentech’s Tecentriq as First-Ever Therapy for a Certain Advanced Rare Sarcoma Called Alveolar Soft Part Sarcoma (ASPS)
South San Francisco, CA – December 9th, 2022 – Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) for ...
FDA Approves Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer
Tecentriq is the first and only cancer immunotherapy approved for treatment of NSCLC in the adjuvant setting Approval based on the Phase III IMpower010 study showing adjuvant Tecentriq improved...
FDA Approves Genentech’s Tecentriq plus Cotellic and Zelboraf for People With Advanced Melanoma
South San Francisco, CA – July 30, 2020 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq...
FDA Approves Genentech’s Tecentriq in Combination With Avastin for People With Hepatocellular Carcinoma
South San Francisco, CA – May 29, 2020 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Genentech’s Tecentriq as a First-Line Monotherapy for Certain People With Metastatic Non-Small Cell Lung Cancer
South San Francisco, CA – May 18, 2020 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Genentech’s Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for The Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
South San Francisco, CA – December 3, 2019 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq...
FDA Approves Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Adults With Extensive-Stage Small Cell Lung Cancer
South San Francisco, CA – March 18, 2019 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Melanoma, Small Cell Lung Cancer